Anti-vascular Endothelial Growth Factor-B As A Biologic For Treating Eye Disease
Funder
National Health and Medical Research Council
Funding Amount
$464,295.00
Summary
We plan to show that an engineered antibody fragment against vascular endothelial growth factor-B is an effective therapeutic drug for two eye diseases, corneal neovascularization and age-related macular degeneration. The innovative aspects of this approach are that it may be safer, and have a different spectrum of activity, than existing ophthalmic anti-angiogenic agents. Furthermore, it may be effective for corneal disease when administered as an eye-drop.